Video

Major considerations and updates in immunotherapy for advanced prostate cancer

Author(s):

Urology Times staff

“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.

In this video, Susan F. Slovin, MD, PhD, discusses takeaways of her presentation on immunotherapy in advanced prostate cancer, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, and upcoming research. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.

Related Videos
Dr Louise Kostos answers a question during a Zoom video interview
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Trial launches of CBP/p300 inhibitor in mCRPC
March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke
Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Michael R. Folkert, MD, PhD, answers a question during a Zoom video interview
March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor
"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
© 2025 MJH Life Sciences

All rights reserved.